文献速递肿瘤 PET/CT骨显像与常规 SPECT

多发性骨髓瘤合并前列腺癌患者化疗后骨髓瘤68Ga-PSMA摄取变化

The Change of 68Ga-Prostate-Specific Membrane Antigen Uptake in Myeloma After Chemotherapy in a Patient With Multiple Myeloma and Concurrent Prostate Cancer.
PubMed 文献 · Clin Nucl Med · 2020-01-01

一例76岁有前列腺癌病史的男性因右跟骨骨病变行68Ga-PSMA-11 PET/CT,显示附肢骨骼多发PSMA表达的溶骨性病变,右跟骨活检证实为浆细胞瘤。数周期化疗后患者达血清学严格完全缓解,随访PET/CT示既往PSMA高摄取骨病变摄取显著降低而CT形态学无变化,提示化疗后骨髓瘤PSMA表达降低源于治疗反应。

要点

  • 骨髓瘤骨病变可表达PSMA,68Ga-PSMA PET/CT可显示多发PSMA高摄取溶骨性病变。
  • 化疗后血清学严格完全缓解者,随访PET/CT示PSMA摄取显著降低而CT形态学无变化。
  • 骨髓瘤化疗后PSMA表达降低提示治疗反应,PSMA PET或可用于疗效评估。

核心结论

  • 化疗后多发性骨髓瘤骨病变的68Ga-PSMA-11摄取显著降低,提示PSMA表达降低源于治疗反应。

研究设计与样本

  • 单个病例报告:76岁有前列腺癌病史的男性,因右跟骨骨病变行68Ga-PSMA-11 PET/CT及活检,化疗后随访PET/CT。

主要发现

  • 68Ga-PSMA-11 PET/CT示附肢骨骼多发PSMA表达的溶骨性骨病变,右跟骨活检证实为浆细胞瘤。
  • 数周期化疗后患者达血清学严格完全缓解,随访PET/CT示既往PSMA高摄取骨病变摄取显著降低,CT上无形态学变化。

临床怎么用

  • 对骨髓瘤合并前列腺癌患者,68Ga-PSMA PET/CT所示骨病变PSMA摄取降低可能反映化疗后治疗反应。

局限性

  • 仅为单个病例报告,结论需更大样本验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

A bone lesion in the right calcaneus was found in a 76-year-old man with a history of prostate cancer. Ga-PSMA-11 PET/CT showed multiple PSMA-expressing lytic bone lesions in appendicular skeleton. Biopsy of the lesion in the right calcaneus confirmed plasmacytoma. After several cycles of chemotherapy, the patient was in serologically stringent complete remission. The follow-up PET/CT showed a significant reduction of Ga-PSMA-11 uptake in the previously PSMA-avid bone lesions without morphological changes on CT. The reduction of PSMA expression in myelomas after chemotherapy is suggested to result from the treatment response.

来源:Clin Nucl Med,查看原文。版权归原作者所有。

引用

  1. Pan Q, Luo Y, Ma Y, et al. The Change of 68Ga-Prostate-Specific Membrane Antigen Uptake in Myeloma After Chemotherapy in a Patient With Multiple Myeloma and Concurrent Prostate Cancer. Clin Nucl Med. 2020. PMID: 33086276. doi:10.1097/RLU.0000000000003339

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。